Skip to main content
Future Journal of Pharmaceutical Sciences
Fig. 18 | Future Journal of Pharmaceutical Sciences

Fig. 18

From: Neuroprotective action of Smilax china ethanolic bark extract in treatment of a prominent aging disorder: Parkinson’s disease induced by rotenone

Fig. 18

Stained images of vagus nerve longitudinal section isolated from respective groups a Group-1 (Control): Normal nerve tissue which is not showing any sign of axonal inflammation and degenerative changes b Group-2 (Induction): Lipid degenerated axons showing a peripheral axonal loss, inflammation and degeneration (black arrow) and alpha-synuclein accumulation (red arrow) c Group-3 (Standard): No axonal degeneration, inflammation, and there is no alpha-synuclein accumulation d Group-4 (Treatment-I): minimum axonal degeneration, inflammation(black arrow) and minimum alpha-synuclein accumulation (red arrow). e Group-5 (Treatment-II): Major recovery of the axonal degeneration and inflammation H & E, (hematoxylin and eosin) 10X

Back to article page